KM Research Hub
← 返回论文库
部分完成 入排:符合 图源:可得 入排置信度 0.98

Adjuvant Epirubicin Plus Cyclophosphamide Followed by Taxanes With or Without Carboplatin in Early-Stage Triple-Negative Breast Cancer (RJBC 1501): A Randomized Phase III Trial.

Xiaosong Chen, Jiahui Huang, Haoting Shi, Juanying Zhu, Weizhu Wu, Guolin Ye, Qi He, Yong Shi, Anqin Zhang, Xiaohong Xie, Xiaodong Wang, Xiangjing Chen, Weili Wu, Jundong Wu, Zhian Li, Zhanwen Li, Yuechu Dai, Weili Ren, Qing Shao, Yongan Chen, Yong Zeng, Fengzhe Zhang, Shuwen Dong, Mark Daniel Pegram, Kunwei Shen

J Clin Oncol 44(3) 143-152

PMID41365333
PMCIDPMC12794722
DOI10.1200/JCO-25-02412
发表日期2025-12-09
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
摘要

摘要

PURPOSE: To evaluate the efficacy and safety of adjuvant epirubicin plus cyclophosphamide followed by taxanes (EC-T) versus EC-T plus carboplatin (EC-TCb) in patients with early-stage triple-negative breast cancer (TNBC). PATIENTS AND METHODS: In this phase III trial, patients with TNBC with node-positive or node-negative (tumor size ≥1.0 cm) disease who received definitive surgery, were stratified by lymph node status and randomly assigned in a 1:1 ratio to receive four cycles of EC followed by four cycles T with or without carboplatin adjuvant chemotherapy. The primary end point was disease-free survival (DFS). Secondary end points included distant DFS (DDFS), overall survival (OS), and safety. This study had 80% power to detect a DFS hazard ratio (HR) of 0.64, with a two-sided type I error of 0.05. RESULTS: A total of 786 patients were randomly assigned to receive EC-T (n = 391) or EC-TCb (n = 395) between March 2016 and March 2023. With a median follow-up of 4.52 (IQR, 2.83-6.06) years, 62 and 41 events were reported in the EC-T and EC-TCb arm, respectively. Adding carboplatin significantly improved DFS (HR, 0.66; [95% CI, 0.44 to 0.97]; P = .034), DDFS (HR, 0.61 [95% CI, 0.38 to 0.98]; P = .040), and OS (HR, 0.39 [95% CI, 0.16 to 0.94]; P = .029). Grade 3 to 4 adverse events were more frequent among the EC-TCb arm (49.9%) than the EC-T arm (38.7%), primarily driven by higher incidence of neutropenia (47.0% v 37.8%) and thrombocytopenia (4.5% v 0%). Other grade 3 to 4 toxicities were comparable. CONCLUSION: Adding carboplatin to adjuvant EC-T chemotherapy significantly improves DFS, DDFS, and OS in patients with early-stage TNBC. Although increased hematologic toxicity was observed, no new safety signals emerged.

KM 提取结果

4 个 Figure · 14 个 KM 面板

进入结果中心
KM Figure3 个面板

FIG 2.

FIG 2. Kaplan-Meier analysis of (A) DFS, (B) DDFS, and (C) OS in ITT population. Stratified HRs and its 95% CI were reported with their corresponding stratified Log-rank P value. Cb, carboplatin; DFS, disease-free survival; DDFS, distant DFS; EC-T, epirubicin plus cyclophosphamide followed by taxanes; EC-TCb, EC-T plus carboplatin; HR, hazard ratio; ITT, intention-to-treat; OS, overall survival.

A

DFS

FIG 2. · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 FIG 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
B

DDFS

FIG 2. · Panel B

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B 是同一 FIG 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
C

OS

FIG 2. · Panel C

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel C 是同一 FIG 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 1:flat topline artifact
查看结果
KM Figure3 个面板

FIG A2.

FIG A2. Kaplan-Meier analysis of (A) disease-free survival, (B) distant disease-free survival, and (C) OS in PPS population. Stratified HRs and its 95% CI were reported. Cb, carboplatin; DDFS, distant DFS; DFS, disease-free survival; EC-T, epirubicin plus cyclophosphamide followed by taxanes; EC-TCb, EC-T plus carboplatin; HR, hazard ratio; OS, overall survival; PPS, per-protocol set.

A

DFS

FIG A2. · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 FIG A2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 2:extreme upward reversal
查看结果
B

DDFS

FIG A2. · Panel B

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B 是同一 FIG A2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 2:extreme upward reversal
查看结果
C

OS

FIG A2. · Panel C

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel C 是同一 FIG A2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 1:extreme upward reversal曲线 2:flat topline artifact
查看结果
KM Figure4 个面板

FIG A3.

FIG A3. Kaplan-Meier plot of DFS curve stratified by (A) age at diagnosis and (B) HER2 status. HER2-low indicated tumors with HER2 IHC status 1+ to 2+. Cb, carboplatin; DFS, disease-free survival; EC-T, epirubicin plus cyclophosphamide followed by taxanes; EC-TCb, EC-T plus carboplatin; HER2, human epidermal growth factor receptor 2; IHC, immunohistochemistry.

A

DFS

FIG A3. · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 FIG A3. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
A_2

DFS

FIG A3. · Panel A_2

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A_2 是同一 FIG A3. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
B

DFS

FIG A3. · Panel B

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel B 是同一 FIG A3. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线缺失:预期 2 条,实际恢复 1 条曲线 1:off origin start曲线 2:very low support曲线 2:extreme jump
查看结果
B_4

DFS

FIG A3. · Panel B_4

failed 待 EXE 对齐 预期 2 条 已提取 0 条

Panel B_4 是同一 FIG A3. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线缺失:预期 2 条,实际恢复 0 条曲线 1:off origin start曲线 1:extreme upward reversal曲线 2:off origin start
No curves extracted
查看结果
KM Figure4 个面板

FIG A5.

FIG A5. DFS among HRR tested population. (A) BRCA mutated population; (B) BRCA wild-type population; (C) HRR-mutated population; (D) HRR wild-type population. HRR test was performance among 138 patients (17.6%). HR reported with 95% CI. Cb, carboplatin; DFS, disease-free survival; EC-T, epirubicin plus cyclophosphamide followed by taxanes; EC-TCb, EC-T plus carboplatin; HR, hazard ratio; HRR, homologous recombination repair.

A

DFS

FIG A5. · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 FIG A5. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
A_2

DFS

FIG A5. · Panel A_2

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A_2 是同一 FIG A5. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
B

DFS

FIG A5. · Panel B

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B 是同一 FIG A5. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
B_4

DFS

FIG A5. · Panel B_4

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B_4 是同一 FIG A5. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
其他 Figure(4,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIG 1.FIG 1. Patient disposition depicted by CONSORT diagram. Of 1,022 patients who were screened, 236 patients were not randomly assigned because of the following reasons: refuse to participate (n = 233) and did not have documented TNBC records (n = 3). AE, adverse event; Cb, carboplatin; EC-T, epirubicin plus cyclophosphamide followed by taxanes; EC-TCb, EC-T plus carboplatin; ITT, intention-to-treat; PPS, per-protocol set; TNBC, triple-negative breast cancer.
非 KM Figure
FIG 3.FIG 3. Subgroup analysis of DFS. a Excluded 12 patients who did not received any taxanes treatment. ALND, axillary lymph node dissection; BCS, breast conserving surgery; Cb, carboplatin; DFS, disease-free survival; EC-T, epirubicin plus cyclophosphamide followed by taxanes; EC-TCb, EC-T plus carboplatin; HER2, human epidermal growth factor receptor 2; HR, hazard ratio; IHC, immunohistochemistry; SLNB, sentinel lymph node biopsy.
非 KM Figure
FIG A1.FIG A1. Cumulative incidence curve of first DFS event encountered. (A) Locoregional recurrence, (B) distant recurrence, (C) contralateral breast cancer, and (D) second primary malignancy. Cumulative incidence was estimated using Fine and Gray competing risk model, accounting mortality as competing risk of each outcome, respectively. BC, breast cancer; Cb, carboplatin; EC-T, epirubicin plus cyclophosphamide followed by taxanes; EC-TCb, EC-T plus carboplatin.
非 KM Figure
FIG A4.FIG A4. Subgroup analysis of DDFS. a Excluded 12 patients who did not receive any taxanes treatment. ALND, axillary lymph node dissection; BCS, breast conserving surgery; Cb, carboplatin; DDFS, distant disease-free survival; EC-T, epirubicin plus cyclophosphamide followed by taxanes; EC-TCb, EC-T plus carboplatin; HR, hazard ratio; SLNB, sentinel lymph node biopsy.
非 KM Figure